Кардиодермальные синдромы: полный список литературы

  • Bolling MC, Jonkman MF. Skin and heart: une liaison dangereuse. Exp Dermatol 2009;18:658–68.
  • Gerull B. Skin-heart connection: what can the epidermis tell us about the myocardium in arrhythmogenic cardiomyopathy? Circ Cardiovasc Genet 2014;7:225–7.
  • Hwang H, Liu F, Levin MD, et al. Isolating primary melanocyte-like cells from the mouse heart. J Vis Exp 2014;91:4357.
  • Brito FC, Kos L. Timeline and distribution of melanocyte precursors in the mouse heart. Pigment Cell Melanoma Res 2008;21:464–70.
  • Baujat G, Le Merrer M. Ellis-van Creveld syndrome. Orphanet J Rare Dis 2007;2:27.
  • Correa R, Salpea P, Stratakis CA. Carney complex: an update. Eur J Endocrinol 2015;173:M85–97.
  • Horvath A, Stratakis CA. Carney complex and lentiginosis. Pigment Cell Melanoma Res 2009;22:580–7.
  • Bezniakow N, Gos M, Obersztyn E. The RASopathies as an example of RAS/MAPK pathway disturbances—clinical presentation and molecular pathogenesis of selected syndromes. Dev Period Med 2014;18:285–96.
  • Morice-Picard F, Ezzedine K, Delrue MA, et al. Cutaneous manifestations in Costello and cardiofaciocutaneous syndrome: report of 18 cases and literature review. Pediatr Dermatol 2013;30:665–73.
  • Pierpont ME, Magoulas PL, Adi S, et al. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2014;134:e1149–62.
  • Allanson JE, Annerã©N GÃ, Aoki Yo et al. Cardio-facio-cutaneous syndrome: does genotype predict phenotype? Am J Med Genet C Semin Med Genet 2011;157C:129–35.
  • Siegel DH, McKenzie J, Frieden IJ, et al. Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome. Br J Dermatol 2011;164:521–9.
  • Alves-Pereira D, Berini-Aytes L, Gay-Escoda C. Ellis-van Creveld syndrome. Case report and literature review. Med Oral Patol Oral Cir Bucal 2009;14:E340–3.
  • Kurian K, Shanmugam, Harsh Vardah T, et al. Chondroectodermal dysplasia (Ellis-van Creveld syndrome): a report of three cases with review of literature. Indian J Dent Res 2007;18:31–4.
  • Galdzicka M, Patnala, Hirshman MG, et al. A new gene, EVC2, is mutated in Ellis-van Creveld syndrome. Mol Genet Metab 2002;77:291–5.
  • Tompson SW, Ruiz-Perez VL, Blair HJ, et al. Sequencing EVC and EVC2 identifies mutations in two-thirds of Ellis-van Creveld syndrome patients. Hum Genet 2007;120:663–70.
  • Molho-Pessach V, Lerer I, Abeliovich D, et al. The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am J Hum Genet 2008;83:529–34.
  • Baldwin SA, Yao SYM, Hyde RJ, et al. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 2005;280:15880–7.•Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis 2008;3:13.
  • Kalev I, Muru K, Teek R, et al. LEOPARD syndrome with recurrent PTPN11 mutation Y279C and different cutaneous manifestations: two case reports and a review of the literature. Eur J Pediatr 2010;169:469–73.
  • Pandit B, Sarkozy A, Pennacchio LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007;39:1007–12.
  • Koudova M, Seemanova E, Zenker M. Novel BRAF mutation in a patient with LEOPARD syndrome and normal intelligence. Eur J Med Genet 2009;52:337–40.
  • Agarwal P, Gupta K, Gutch M, et al. The other side of Turner’s: Noonan’s syndrome. Indian J Endocrinol Metab 2013;17:794–8.
  • Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 2005;6:45–68.
  • Ekvall S, Wilbe M, Dahlgren J, et al. Mutation in NRAS in familial Noonan syndrome—case report and review of the literature. BMC Med Genet 2015;16:95.
  • Uitto J. Rare heritable skin diseases: targets for regenerative medicine. J Invest Dermatol 2012;132:2485–8.
  • Marconi B, Bobyr I, Campanati A, et al. Pseudoxanthoma elasticum and skin: clinical manifestations, histopathology, pathomechanism, perspectives of treatment. Intractable Rare Dis Res 2015;4:113–22.
  • Li Q, Jiang Q, Pfendner E, et al. Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms. Exp Dermatol 2009;18:1–11.
  • Chassaing N, Martin L, Calvas P, et al. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet 2005;42:881–92.
  • Varadi A, Szabó Z, Pomozi V, et al. ABCC6 as a target in pseudoxanthoma elasticum. Curr Drug Targets 2011;12:671–82.
  • Uitto J, Li Q, Jiang Q. Pseudoxanthoma elasticum: molecular genetics and putative pathomechanisms. J Invest Dermatol 2010;130:661–70.
  • Jiang Q, Endo M, Dibra F, et al. Pseudoxanthoma elasticum is a metabolic disease. J Invest Dermatol 2009;129:348–54.
  • Braun SA, Finis D, Helbig D. [Pseudoxanthoma elasticum. More than a skin problem]. Hautarzt 2013;64:222, 224-5.
  • De Zaeytijd J, Vanakker OM, Coucke PJ, et al. Added value of infrared, red-free and autofluorescence fundus imaging in pseudoxanthoma elasticum. Br J Ophthalmol 2010;94:479–86.
  • Georgalas I, Papaconstantinou D, Koutsandrea C, et al. Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag 2009;5:81–9.
  • Sherer DW, Singer G, Uribarri J, et al. Oral phosphate binders in the treatment of pseudoxanthoma elasticum. J Am Acad Dermatol 2005;53:610–15.
  • LaRusso J, Jiang Q, Li Q, et al. Ectopic mineralization of connective tissue in Abcc6-/- mice: effects of dietary modifications and a phosphate binder—a preliminary study. Exp Dermatol 2008;17:203–7.
  • Jiang Q, Li Q, Uitto J. Aberrant mineralization of connective tissues in a mouse model of pseudoxanthoma elasticum: systemic and local regulatory factors. J Invest Dermatol 2007;127:1392–402.
  • Quaglino D, Boraldi F, Barbieri D, et al. Abnormal phenotype of in vitro dermal fibroblasts from patients with pseudoxanthoma elasticum (PXE). Biochim Biophys Acta 2000;1501:51–62.
  • Passi A, Albertini R, Baccarani Contri M, et al. Proteoglycan alterations in skin fibroblast cultures from patients affected with pseudoxanthoma elasticum. Cell Biochem Funct 1996;14:111–20.
  • Protonotarios N, Tsatsopoulou A. Naxos disease: cardiocutaneous syndrome due to cell adhesion defect. Orphanet J Rare Dis 2006;1:4.
  • Boulé S, Fressart V, Laux D, et al. Expanding the phenotype associated with a desmoplakin dominant mutation: carvajal/naxos syndrome associated with leukonychia and oligodontia. Int J Cardiol 2012;161:50–2.
  • Chalabreysse L, Senni F, Bruyère P, et al. A new hypo/oligodontia syndrome: carvajal/naxos syndrome secondary to desmoplakindominant mutations. J Dent Res 2011;90:58–64.
  • Schönberger J, Seidman CE. Many roads lead to a broken heart: the genetics of dilated cardiomyopathy. Am J Hum Genet 2001;69:249–60.
  • Antonov NK, Kingsbery MY, Rohena LO, et al. Early-onset heart failure, alopecia, and cutaneous abnormalities associated with a novel compound heterozygous mutation in desmoplakin. Pediatr Dermatol 2015;32:102–8.
  • Salam AA, Remadevi KS, Kurup RP. Naxos disease and Carvajal variant. Indian Pediatr 2013;50:596–8.
  • Beighton P, De Paepe A, Steinmann B, et al. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 1998;77:31–7.
  • Callewaert B, Malfait F, Loeys B, et al. Ehlers-Danlos syndromes and Marfan syndrome. Best Pract Res Clin Rheumatol 2008;22:165–89.
  • Colige A, Nuytinck L, Hausser I, et al. Novel types of mutation responsible for the dermatosparactic type of Ehlers-Danlos syndrome (Type VIIC) and common polymorphisms in the ADAMTS2 gene. J Invest Dermatol 2004;123:656–63.
  • Silverman DI, Gray J, Roman MJ, et al. Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Coll Cardiol 1995;26:1062–7.
  • Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407–11.
  • Pereira L, Andrikopoulos K, Tian J, et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997;17:218–22.
  • Berk DR, Bentley DD, Bayliss SJ, et al. Cutis laxa: a review. J Am Acad Dermatol 2012;66:842. e1–17.
  • Mohamed M, Kouwenberg D, Gardeitchik T, et al. Metabolic cutis laxa syndromes. J Inherit Metab Dis 2011;34:907–16.
  • Gonzalo S, Kreienkamp R. DNA repair defects and genome instability in Hutchinson-Gilford Progeria syndrome. Curr Opin Cell Biol 2015;34:75–83.
  • Ikeda Y, Kumagai H, Motozawa Y, et al. Understanding vascular diseases: lessons from premature aging syndromes. Can J Cardiol 2016;32:650–8.
  • Vidak S, Foisner R. Molecular insights into the premature ageing disease progeria. Histochem Cell Biol 2016;145:401–17. Haugaa KH, Haland TF, Leren IS, et al. Arrhythmogenic right ventricular cardiomyopathy, clinical manifestations, and diagnosis. Europace 2016;18:965–72.
  • Asimaki A, Kleber AG, Saffitz JE. Pathogenesis of arrhythmogenic cardiomyopathy. Can J Cardiol 2015;31:1313–24.
  • Sakiyama T, Kubo A. Hereditary palmoplantar keratoderma “clinical and genetic differential diagnosis”. J Dermatol 2016;43:264–74.•Pfendner EG, Lucky AW. Dystrophic epidermolysis bullosa. In: Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews(R). eds. Seattle, WA: University of Washington, 1993.
  • Shinkuma S. Dystrophic epidermolysis bullosa: a review. Clin Cosmet Investig Dermatol 2015;8:275–84.
  • Martens MA, Wilson SJ, Reutens DC. Research review: Williams syndrome: a critical review of the cognitive, behavioral, and neuroanatomical phenotype. J Child Psychol Psychiatry 2008;49:576–608.
  • Collins RT II. Cardiovascular disease in Williams syndrome. Circulation 2013;127:2125–34.
  • Sybert VP, Mccauley E. Turner’s syndrome. N Engl J Med 2004;351:1227–38.
  • Pinsker JE. Clinical review: Turner syndrome: updating the paradigm of clinical care. J Clin Endocrinol Metab 2012;97:E994–1003.
  • Sommer C, Henrique-Silva F. Trisomy 21 and Down syndrome: a short review. Braz J Biol 2008;68:447–52.
  • Desai SS. Down syndrome: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:279–85.
  • Wanders RJA, Waterham HR, Leroy BP. Refsum disease. In: Pagon RA, Adam MP, Ardinger HH. in GeneReviews(R). et al eds. Seattle, WA: University of Washington, 1993.
  • Wierzbicki AS. Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review. Biochem Soc Trans 2007;35(Pt 5):881–6.
  • Shashi V, Zunich J, Kelly TE, et al. Neuroectodermal (CHIME) syndrome: an additional case with long term follow-up of all reported cases. J Med Genet 1995;32:465–9.
  • Tinschert S, Anton-Lamprecht I, Albrecht-Nebe H, et al. Zunich neuroectodermal syndrome: migratory ichthyosiform dermatosis, colobomas, and other abnormalities. Pediatr Dermatol 1996;13:363–71.
  • Zunich J, Esterly N. Chime syndrome (Zunich Syndrome). In: Ruggieri M, Pascual-Castroviejo I, Rocco C. Neurocutaneous disorders phakomatoses and hamartoneoplastic syndromes. eds. Vienna: Springer, 2008:949–55.